About
TearSolutions Inc., a Delaware corporation based in Charlottesville, VA, has completed a successful 204-patient Phase II Proof of Concept trial for treating ocular surface disease in primary Sjögren’s Syndrome. The study showed statistically significant improvement in both signs and symptoms after two weeks using Lacripep™, a novel 19–amino acid peptide found in healthy tears but deficient in all dry eye forms. Lacripep™ restores corneal epithelial barrier function and sensory nerve activity, improving tear production and quality. Clinical benefits included reduced corneal fluorescein staining and increased tear production—key measures also used in the FDA approvals of Xiidra and Restasis.
Charlottesville